

Kariya Pharmaceuticals IVS

Ole Maaløes Vej 3
2200 København N

Årsrapport
18. januar 2018 - 31. december 2018

**Årsrapporten er fremlagt og godkendt på
selskabets ordinære generalforsamling den**

21/05/2019

Ian Rodney Laquian
Dirigent

Indhold**Virksomhedsoplysninger**

Virksomhedsoplysninger	3
------------------------------	---

Påtegninger

Ledelsespåtegning	4
-------------------------	---

Ledelsesberetning

Ledelsesberetning	5
-------------------------	---

Årsregnskab

Anvendt regnskabspraksis	6
--------------------------------	---

Resultatopgørelse	7
-------------------------	---

Balance	8
---------------	---

Virksomhedsoplysninger

Virksomheden

Kariya Pharmaceuticals IVS

Ole Maaløes Vej 3

2200 København N

e-mailadresse: ian.laquian@kariyapharma.com

CVR-nr: 39270684

Regnskabsår: 18/01/2018 - 31/12/2018

Ledelsespåtegning

Today, the Board of Directors have discussed and approved the annual report of Kariya Pharmaceuticals IVS for the financial year 18 January - 31 December 2018.

The annual report is prepared in accordance with the Danish Financial Statements Act.

In my opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2018 and of the results of the Company's operations for the financial year 18 January - 31 December 2018.

Further, in my opinion, the management's review gives a fair review of the matters discussed in the Management's review.

I recommend that the annual report be approved at the annual general meeting.

Copenhagen, den 07/02/2019

Direktion

Ian Rodney Laquian

Ledelsesberetning

Business review

The primary activity of the company is research and development within biotechnology.

Financial review

As of 31 december 2018 the balance sheet shows equity of 100 DKK.

Events after the balance sheet date

No events materially affecting the Company's financial position have occurred subsequent to the financial year-end.

Anvendt regnskabspraksis

Årsrapporten er aflagt i overensstemmelse med årsregnskabslovens bestemmelser for Regnskabsklasse B, mikrovirksomhed.

Recognition and measurement

Assets are recognised in the balance sheet when it is probable as a result of a prior event that future economic benefits will flow to the Entity, and the value of the asset can be measured reliably.

Liabilities are recognised in the balance sheet when the Entity has a legal or constructive obligation as a result of a prior event, and it is probable that future economic benefits will flow out of the Entity, and the value of the liability can be measured reliably.

On initial recognition, assets and liabilities are measured at cost. Measurement subsequent to initial recognition is effected as described below for each financial statement item.

Anticipated risks and losses that arise before the time of presentation of the annual report and that confirm or invalidate affairs and conditions existing at the balance sheet date are considered at recognition and measurement.

Income is recognised in the income statement when earned, whereas costs are recognised by the amounts attributable to this financial year

Balance sheet

Cash

Cash comprise cash and short term securities which are readily convertible into cash and subject only to minor risks of changes in value.

Resultatopgørelse 18. jan. 2018 - 31. dec. 2018

	Note	2018 kr.
Bruttoresultat		0
Ordinært resultat før skat		0
Skat af årets resultat		0
Årets resultat		0
Forslag til resultatdisponering		
Overført resultat		0
I alt		0

Balance 31. december 2018

Aktiver

	Note	2018 kr.
Likvide beholdninger		100
Omsætningsaktiver i alt		100
Aktiver i alt		100

Balance 31. december 2018

Passiver

	Note	2018 kr.
Registreret kapital mv.		100
Overført resultat		0
Egenkapital i alt		100
Passiver i alt		100